Abstract
The current state of relapse prevention in schizophrenia is characterized by a paradoxical situation. On the one hand, for almost 40 years now we have been in possession of highly effective neuroleptic drugs, the prophylactic value of which has been clearly proven in numerous controlled studies (Davis 1980; Kane 1987). On the other hand, we are still confronted with the disconcerting fact that under routine treatment conditions 50% of schizophrenic patients suffer a relapse within one year of their most recent episode (Gaebel and Pietzcker 1985) and that, on average, schizophrenic patients spend between 15% and 20% of their time after their first illness in psychiatric hospitals due to the frequent occurrence of relapses (Maurer and Biehl 1988; Gmür and Tschopp 1988).
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Reference
Bäuml J, Kissling W, Meurer C, Wais A, Lauter H (1991) Informationszentrierte Angehörigengruppen zur Complianceverbesserung bei schizophrenen Patienten. Psychiat Prax 18:48–54
Bosch G, Pietzcker A (1975) Anhang zum Bericht über die Lage der Psychiatrie in der Bundesrepublik Deutschland. Bundestag, Drucksache 7/4201, pp 344–360
Davis JM (1980) Antipsychotic drugs. In: Kaplan HI, Freedman AM, Sadock BJ (ed) Comprehensive textbook of psychiatry, 3rd edn. Williams and Wilkins, Baltimore
Gaebel W, Pietzcker A (1983) Indikation zur neuroleptischen Langzeitmedikation — Standardverfahren oder individualprognostisch geleitete Intervention? Nervenarzt 54:467–476
Gaebel W, Pietzcker A (1985) One year outcome of schizophrenic patients — the interaction of chronicity and neuroleptic treatment. Pharmacopsychiat 18:235–239
Gmür M, Tschopp A (1988) Die Behandlungskontinuität bei schizophrenen Patienten in der Ambulanz. Eine Fünfjahresnachuntersuchung. Nervenarzt 59:727–730
Johnson DAW (1979) Further observations on the duration of depot neuroleptic maintenance therapy in schizophrenia. Br J Psychiatry 135:524–530
Kane JM (1985) Compliance issues in outpatient treatment. J Clin Psychopharmacol 5
Kane JM (1987) Treatment of schizophrenia. Schizophrenia Bull 13/1
Kissling W (1988) Consensus regarding indication for prophylactic neuroleptic treatment -necessary, but unattainable? In: Barnes TRE (ed) Depot neuroleptics — a consensus. Antwerp, 19 Nov 1987. Mediscript, London, pp 41–46
Maurer K, Biehl H (1988) Klinikaufenthalte und produktive Rückfälle bei ersterkrankten Schizophrenen. Determinanten des Zeitverlaufs zwischen stationären Aufnahmen bzw. schizophrenen Rezidiven über fünf Jahre. Nervenheilkunde 7:279–290
Pietzcker A (1987) Neuroleptische Langzeit-Medikation in der ambulanten Behandlung schizophren Kranker. Promonta-Schriften, Hamburg
Shepherd M, Watt D, Falloon I, Smeeton N (1989) The natural history of schizophrenia: a five-year follow-up study of outcome and prediction in a representative sample of schizophrenics. Psychological Medicine, Monograph Suppl 15. Cambridge University Press, Cambridge
Smith J, Birchwood M (1990) Relatives and patients as partners in the management of schizophrenia. The development of a service model. Br J Psychiatry 156:654–660
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Kissling, W. (1991). Introduction. In: Kissling, W. (eds) Guidelines for Neuroleptic Relapse Prevention in Schizophrenia. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-86922-8_1
Download citation
DOI: https://doi.org/10.1007/978-3-642-86922-8_1
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-53985-8
Online ISBN: 978-3-642-86922-8
eBook Packages: Springer Book Archive